Facial Erythema Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Facial Erythema Treatment Market Analysis
Facial erythema can occur due to any skin injury or inflammation and is primarily seen in fair-skinned people. Rosacea and dermatitis are few inflammatory skin disease that causes facial erythema. Rosacea is a common skin disease, which causes redness and visible blood vessels on the face. As per the National Rosacea Society, United States, the prevalence of rosacea was highest when self-reported, with a rate of 9.71% ( 737,960,000), while the rate of dermatologist-diagnosed rosacea was 5.53% (420,280,000) in 2018. Although there is no cure, treatments can control and reduce the signs and symptoms associated with the disease. With the rising burden of disease and more common occurrence in changing lifestyle, the awareness among the physicians and societies have also increased, which further drives the demand of this market.
Facial Erythema Treatment Market Trends
This section covers the major market trends shaping the Facial Erythema Treatment Market according to our research experts:
Antibiotics Segment is Estimated to Hold the Largest Share of the Market
By drug type, the facial erythema treatment market has been segmented into Antibiotics, Antifungal, Antihistamines, Corticosteroids, and Others. Antibiotics can reduce the number of acne pimples and bacterial inflammation or redness. It is most commonly preferred by physicians and doctors as compared to other types for early relief from the disease. Topical metronidazole antibiotic is commonly used as a first-line agent. The high demand for antibiotics in the treatment of rosacea is the main factor for the growth of the market. However, there are certain side effects associated with the usage of antibiotics, including bloating, loss of appetite, abdominal pain, and many others, which is expected to restrain their adoption in the forecast period.
North America dominates the Facial Erythema Treatment Market
North America has multiple factors, which support the growth of this market, better than other geographic regions. Some factors include high healthcare expenditure by the government each year on pharmaceuticals and medical devices and awareness in the society. As per the estimates of the National Rosacea Society (NRS), in 2018 about 16 million Americans suffer from rosacea. Such trends are expected to push more patients suffering from symptoms of facial erythema to approach clinics and hospitals, which boosts the studied market in the region. The region is also supported by multiple international companies being collaborated with many major hospital chains, which drives the business of the studied market.
Asia-Pacific is expected to be explored more over the forecast period by the international companies because of the larger target patient pool, changing lifestyle and rapid population growth, better economic growth with higher importance to healthcare facilities and increase in research and development activities.
Facial Erythema Treatment Industry Overview
The major players in the facial erythema treatment market includes Astellas Pharma, Bausch Health Companies Inc., GlaxoSmithKline plc, LEO Pharma A/S, Merck & Co., Inc., Nestlé S.A. (Galderma), Merck & Co., Inc., Novartis International AG, and Sanofi, which provides these products across the globe.
Facial Erythema Treatment Market Leaders
-
Bausch Health Companies Inc.
-
LEO Pharma A/S
-
Nestlé S.A. (Galderma)
-
Merck & Co., Inc.
-
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Facial Erythema Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Burden of Skin Disorders
- 4.2.2 Growth in Research and Development related to Dermatological Diseases
-
4.3 Market Restraints
- 4.3.1 Increased Use of Generic Drugs
- 4.3.2 Stringent Regulations
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Drug Type
- 5.1.1 Antibiotics
- 5.1.2 Antifungal
- 5.1.3 Antihistamines
- 5.1.4 Corticosteroids
- 5.1.5 Others
-
5.2 By Mode of Administration
- 5.2.1 Topical
- 5.2.2 Oral
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Astellas Pharma
- 6.1.2 Bausch Health Companies Inc.
- 6.1.3 GlaxoSmithKline plc
- 6.1.4 LEO Pharma A/S
- 6.1.5 Merck & Co., Inc.
- 6.1.6 Nestle S.A. (Galderma)
- 6.1.7 Novartis AG
- 6.1.8 Pfizer Inc.
- 6.1.9 Sanofi S.A.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityFacial Erythema Treatment Industry Segmentation
As per the scope of the report, Facial erythema is basically skin redness, noticeable in fair-skinned individuals, which occurs as a result of cutaneous blood vessel dilation and increased blood flow to the skin. A variety of factors, including primary skin diseases and systemic illness may cause facial redness.
| By Drug Type | Antibiotics | |
| Antifungal | ||
| Antihistamines | ||
| Corticosteroids | ||
| Others | ||
| By Mode of Administration | Topical | |
| Oral | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Facial Erythema Treatment Market Research FAQs
What is the current Facial Erythema Treatment Market size?
The Facial Erythema Treatment Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Facial Erythema Treatment Market?
Bausch Health Companies Inc., LEO Pharma A/S, Nestlé S.A. (Galderma), Merck & Co., Inc. and Pfizer Inc. are the major companies operating in the Facial Erythema Treatment Market.
Which is the fastest growing region in Facial Erythema Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Facial Erythema Treatment Market?
In 2024, the North America accounts for the largest market share in Facial Erythema Treatment Market.
What years does this Facial Erythema Treatment Market cover?
The report covers the Facial Erythema Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Facial Erythema Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Facial Erythema Treatment Industry Report
Statistics for the 2024 Facial Erythema Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Facial Erythema Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
